UY35146A - Compuestos y composiciones para el tratamiento de enfermedades parasitarias - Google Patents

Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Info

Publication number
UY35146A
UY35146A UY0001035146A UY35146A UY35146A UY 35146 A UY35146 A UY 35146A UY 0001035146 A UY0001035146 A UY 0001035146A UY 35146 A UY35146 A UY 35146A UY 35146 A UY35146 A UY 35146A
Authority
UY
Uruguay
Prior art keywords
compounds
compositions
treatment
parasitary
diseases
Prior art date
Application number
UY0001035146A
Other languages
English (en)
Spanish (es)
Inventor
Chatterjee Arnab
Nagle Advait
Paraselli Prasuna
Revinder Reddy Kondreddi
Seth Yong Leong
Mishra Pranab
Moreau Robert
Jason Thomas Roland
Wei Lin Sandra Sim
Oliver Simon
Liying Jocelyn Tan
Bryan Ks Yeung
Zou Bin
Bollu Venkatataiah
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of UY35146A publication Critical patent/UY35146A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY0001035146A 2012-11-19 2013-11-19 Compuestos y composiciones para el tratamiento de enfermedades parasitarias UY35146A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728018P 2012-11-19 2012-11-19
US201361847860P 2013-07-18 2013-07-18

Publications (1)

Publication Number Publication Date
UY35146A true UY35146A (es) 2014-06-30

Family

ID=49667630

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035146A UY35146A (es) 2012-11-19 2013-11-19 Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Country Status (19)

Country Link
US (3) US9556169B2 (enExample)
EP (1) EP2925757B1 (enExample)
JP (1) JP6298472B2 (enExample)
CN (1) CN105164124B (enExample)
AR (1) AR093532A1 (enExample)
CY (1) CY1119727T1 (enExample)
DK (1) DK2925757T3 (enExample)
ES (1) ES2655030T3 (enExample)
HR (1) HRP20171998T1 (enExample)
HU (1) HUE037600T2 (enExample)
LT (1) LT2925757T (enExample)
ME (1) ME03042B (enExample)
PL (1) PL2925757T3 (enExample)
PT (1) PT2925757T (enExample)
RS (1) RS56720B1 (enExample)
SI (1) SI2925757T1 (enExample)
TW (1) TWI600654B (enExample)
UY (1) UY35146A (enExample)
WO (1) WO2014078802A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
TW201728325A (zh) 2016-01-21 2017-08-16 諾華公司 治療隱孢子蟲病之化合物及組合物
TWI696615B (zh) * 2016-05-05 2020-06-21 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
WO2018011163A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
EP3526220B1 (en) * 2016-10-13 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Compounds and method for blocking transmission of malarial parasite
EP3609504A4 (en) 2017-03-01 2021-03-03 Anacor Pharmaceuticals, Inc. NEW OXABOROLE ANALOGUES AND USES OF THE LATEST
JP7306997B2 (ja) * 2017-03-20 2023-07-11 ザ・ブロード・インスティテュート・インコーポレイテッド 寄生虫性疾患の処置のための化合物および方法
CA3057377A1 (en) 2017-03-27 2018-10-04 Hydro-Quebec Salts for use in electrolyte compositions or as electrode additives
CN107037148B (zh) * 2017-04-07 2019-11-19 上海药明康德新药开发有限公司 卤泛曲林的高效液相检测方法
JOP20190278A1 (ar) 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US11628593B2 (en) 2017-10-02 2023-04-18 Dal-Tile, Llc Method for manufacturing an engineered stone and an engineered stone
IL279977B2 (en) 2018-07-09 2024-06-01 Boehringer Ingelheim Animal Health Usa Inc Heterocyclic anthelmintic compounds
GB201811695D0 (en) * 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
UY38540A (es) * 2019-01-14 2020-08-31 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
CA3133100A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
BR112021024726A2 (pt) 2019-06-07 2022-01-18 Elanco Tiergesundheit Ag Novos derivados bicíclicos
RU2019123849A (ru) * 2019-07-29 2021-02-01 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Ингибиторы фактора ингибирования миграции макрофагов
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
WO2023275590A1 (en) 2021-06-29 2023-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Detection of phosphoinositides in blood cells as a biomarker for alpha synuclein associated pathologies and a method of treatment of parkinson's disease and the related neurodegenerations
US20250002491A1 (en) 2021-10-04 2025-01-02 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
IL312412A (en) 2021-11-01 2024-06-01 Boehringer Ingelheim Vetmedica Gmbh Pyrrolopyridazine compounds against worms
CA3181279A1 (en) * 2022-03-24 2023-09-24 Bloom Energy Corporation Fuel cell stack assembly including heat sink inserts
US12358305B2 (en) 2022-06-30 2025-07-15 Dal-Tile, Llc Method for manufacturing a decorative element comprising an engineered stone and a decorative element comprising an engineered stone
US12338188B2 (en) 2022-06-30 2025-06-24 Dal-Tile, Llc Method for manufacturing a decorative element comprising an engineered stone and a decorative element comprising an engineered stone
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2024196989A1 (en) * 2023-03-20 2024-09-26 University Of Central Florida Research Foundation, Inc. Anti-malarial therapy
AR132354A1 (es) * 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados de pirazolo[1,5-a]piridina

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034866A1 (en) 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors
EA006626B1 (ru) 1996-07-24 2006-02-24 Дюпон Фармасьютикалз Компани Азолопиримидины, фармацевтическая композиция и способ лечения
EP0995742A4 (en) 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE
JP2001139575A (ja) 1999-11-15 2001-05-22 Fujisawa Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
GB0002312D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
EP1261607B1 (en) * 2000-03-01 2008-11-12 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
AU2001259242A1 (en) 2000-04-28 2001-11-12 Glaxo Group Limited Process for the preparation of chemical compounds
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
AUPR916301A0 (en) 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
KR20040097375A (ko) 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EP1543001B1 (en) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AR050169A1 (es) * 2004-07-16 2006-10-04 Schering Corp Compuesto para el tratamiento de trastornos inflamatorios
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
CA2575808A1 (en) 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
JP2008516962A (ja) 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
JP4935357B2 (ja) 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
DE602005014382D1 (de) * 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
US20080167314A1 (en) 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
US7713975B1 (en) 2005-01-12 2010-05-11 Alcon, Inc. 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
US8993763B2 (en) 2005-09-27 2015-03-31 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
JP2009531274A (ja) 2005-12-07 2009-09-03 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド キナーゼ阻害性ピロロピリジン化合物
US7795273B2 (en) 2005-12-08 2010-09-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
WO2007086080A2 (en) 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
BRPI0712381A2 (pt) 2006-06-06 2012-07-10 Avigen Inc compostos de pirazolo[1,5-a]piridina substituìda e seus métodos de uso
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
US20110021513A1 (en) 2006-09-07 2011-01-27 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
EP2062048A4 (en) 2006-09-12 2009-12-02 Gen Hospital Corp METHOD FOR IDENTIFYING CELL SIGNALING MODULATING COMPOUNDS AND METHOD FOR USING SUCH COMPOSITES
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
KR20090112732A (ko) 2007-01-26 2009-10-28 아이알엠 엘엘씨 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
EP2167058B1 (en) 2007-06-18 2015-08-12 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
JP2010533173A (ja) 2007-07-11 2010-10-21 オークランド・ユニサーヴィシズ・リミテッド ピラゾロ［１，５−ａ］ピリジン、及び癌治療におけるその使用
AU2008275891B2 (en) 2007-07-19 2013-10-10 H.Lundbeck A/S 5-membered heterocyclic amides and related compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AR070487A1 (es) 2008-02-28 2010-04-07 Novartis Ag Derivados de 3- metil- imidazo -( 1,2-b)- piridazina
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
JP5492194B2 (ja) 2008-05-13 2014-05-14 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
JP2009298710A (ja) 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾ［１，２−ｂ］ピリダジン誘導体含有医薬組成物
AU2009267137A1 (en) 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010017046A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Pyrazolo[1,5-a]pyridines as mark inhibitors
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8853125B2 (en) 2008-09-24 2014-10-07 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
ES2403633T3 (es) 2008-12-04 2013-05-20 Proximagen Limited Compuestos de imidazopiridina
WO2010074586A1 (en) 2008-12-23 2010-07-01 Pathway Therapeutics Limited Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives and their use in cancer therapy
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2408753A4 (en) 2009-03-20 2012-11-07 Univ Brandeis COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS
MX2011009796A (es) 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
WO2010117787A2 (en) 2009-03-30 2010-10-14 The Brigham And Women's Hospital, Inc. Inhibiting eph b-3 kinase
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
RU2421455C2 (ru) 2009-07-14 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ 7-АРИЛКАРБАМОИЛ-6-БЕНЗОИЛ-2-МЕТИЛ-3-ФЕНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИН-5-КАРБОКСИЛАТОВ
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TW201113286A (en) 2009-09-03 2011-04-16 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
EP2480548A4 (en) 2009-09-23 2013-02-20 Panmira Pharmaceuticals Llc INDOLIZIN 5-LIPOXYGENASE INHIBITORS
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
US20150291598A1 (en) 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
RS56720B1 (sr) 2018-03-30
SI2925757T1 (en) 2018-01-31
PL2925757T3 (pl) 2018-06-29
US20150344471A1 (en) 2015-12-03
LT2925757T (lt) 2017-12-27
CY1119727T1 (el) 2018-06-27
US9926314B2 (en) 2018-03-27
ME03042B (me) 2018-10-20
TWI600654B (zh) 2017-10-01
WO2014078802A1 (en) 2014-05-22
TW201429967A (zh) 2014-08-01
HUE037600T2 (hu) 2018-09-28
CN105164124A (zh) 2015-12-16
JP6298472B2 (ja) 2018-03-20
DK2925757T3 (en) 2018-01-15
EP2925757B1 (en) 2017-10-04
PT2925757T (pt) 2018-01-09
US20180230145A1 (en) 2018-08-16
CN105164124B (zh) 2017-03-15
ES2655030T3 (es) 2018-02-16
HRP20171998T1 (hr) 2018-02-09
AR093532A1 (es) 2015-06-10
EP2925757A1 (en) 2015-10-07
US20160333012A1 (en) 2016-11-17
US9556169B2 (en) 2017-01-31
JP2016505529A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY39646A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
CO6741217A2 (es) Modulares de receptor de glucagón
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
MX2017015211A (es) Compuestos de naftiridina como inhibidores de quinasa jak.
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
DOP2014000121A (es) Derivados de betulina
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
MX346143B (es) Ligandos del receptor ep1.
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma